Background: Lupus vasculitis (LV) [1] is one of the secondary vasculitides occurring in the setting of systemic lupus erythematosus most commonly affecting small vessels or medium vessels, rarely large vessels. LV is commonly associated with anti-phospholipid syndrome [2].

Objectives: Case Report

Methods: To access practicable treatment modalities in resource poor settings-Nigeria.

Results: Electromyelography-Mononeuritis multiplex, HRT-pulmonary embolism in bilateral pulmonary artery extending into the segmental artery, Doppler USS of both lower limbs-Acute deep vein thrombosis of the left internal jugular vein, ENA panel-positive dsDNA, anti-smith, anti-Ro/anti-La, Antiphospholipid antibody panel [4]: Positive aCL, anti-B2GPI, LAC, thrombocytopenia, anemia.

Renal parameters marginally deranged. Elevated inflammatory markers.

Management High dose corticosteroids, Rescue therapy low dose Rituximab @ days 0,15 patient had minimal response, maintained on low dose prednisolone, azathioprine and physiotherapy. Trial of EUROLUPUS regimen (6 courses) of low dose cyclophosphamide and rituximab for PE & DVT Inferior vena cavae filter for DVT.

Outcome: Regained full power, tone and reflexes of her lower limbs and walked without support after 6 courses of cyclophosphamide. however, she has residual left foot drop undergoing physiotherapy. Renal parameters marginally resolved. Pulmonary embolism and deep vein thrombosis resolved.

Conclusion: Lupus Vasculitis can affect any organ systems. Modalities for treatment are according to the presentation and severity of the disease.

REFERENCES:

Disclosure of Interests: Shalom ONWUALU ONOSENIGBU: None declared.

Olaosebikan.

Management of LV and anti-phospholipid syndrome in bilateral pulmonary artery extending into the segmental artery, Doppler USS of both lower limbs-Acute deep vein thrombosis of the left internal jugular vein, ENA panel-positive dsDNA, anti-smith, anti-Ro/anti-La, Antiphospholipid antibody panel [4]: Positive aCL, anti-B2GPI, LAC, thrombocytopenia, anemia.

Renal parameters marginally deranged. Elevated inflammatory markers.

Management High dose corticosteroids, Rescue therapy low dose Rituximab @ days 0,15 patient had minimal response, maintained on low dose prednisolone, azathioprine and physiotherapy. Trial of EUROLUPUS regimen (6 courses) of low dose cyclophosphamide and rituximab for PE & DVT Inferior vena cavae filter for DVT.

Outcome: Regained full power, tone and reflexes of her lower limbs and walked without support after 6 courses of cyclophosphamide. however, she has residual left foot drop undergoing physiotherapy. Renal parameters marginally resolved. Pulmonary embolism and deep vein thrombosis resolved.

Conclusion: Lupus Vasculitis can affect any organ systems. Modalities for treatment are according to the presentation and severity of the disease.

REFERENCES:

Table 1.

<table>
<thead>
<tr>
<th>Mean ±SD</th>
<th>Median (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>At 1 month</td>
</tr>
<tr>
<td>SLEDAI-2K</td>
<td>7.2±4.3</td>
</tr>
<tr>
<td>SLE-DAS</td>
<td>9.4±6.3</td>
</tr>
<tr>
<td>CLASI-A</td>
<td>9.3±9.8</td>
</tr>
<tr>
<td>Tj</td>
<td>7.0 (27)</td>
</tr>
<tr>
<td>Tj</td>
<td>3.8±4.7</td>
</tr>
<tr>
<td>Pga</td>
<td>1.2±0.5</td>
</tr>
<tr>
<td>LLDAS n (%)</td>
<td>7.5 (0-25)</td>
</tr>
<tr>
<td>Remission n (%)</td>
<td>7 (0-10)</td>
</tr>
</tbody>
</table>

Disclosure of Interests: AstraZeneca: provides funding.

Drug Disclosure of Interests: Francesca Trentin: None declared, Chiara Tani: None declared, Alberto Cau: None declared, Fulvia Ceccarelli: None declared, Fabrizio Conti: None declared, Laura Colodonato: None declared, Lorenzo Dagna: None declared, Ginevra De Marchi: None declared, Giacomo Emmi: None declared, SERENA FASANO: None declared, Laura Monti: None declared, Luca Moroni: None declared, Flavia Riccio: None declared, Matteo Pigat: None declared, Margherita Zen Speakers bureau: GSK, Marta Mosca: None declared, Luca Tinelli: None declared, Giuseppe Zucchi: None declared.